Consolidated Statement of Changes in Equity

Year ended 31 December 2002

	Share capital HK\$'000	Share premium HK\$'000	Contributed surplus HK\$'000	Statutory surplus reserve HK\$'000	Enterprise deve- lopment fund HK\$'000	Exchange fluctuation reserve HK\$'000	Accu- mulated losses HK\$'000	Total HK\$′000
	(note 27)		(note ii)	(note iii)	(note iii)			
At 1 January 2001								
- as previously stated	114,375	95,220	33,474	_	_	198	(55,826)	187,441
Change in accounting policies	,	,	,				(//	,
– provision for long								
service payment (note 2)	-	-	-	-	-	-	(770)	(770)
At 1 January 2001 (as restated)	114,375	95,220	33,474	_		198	(56,596)	186,671
Issue of new shares	134,600	179,276	33,474	_	_	-	(30,370)	313,876
Share issue expenses	-	(3,301)	_	_	_	_	_	(3,301)
Exercise of share options	11,400	-	_	_	_	_	_	11,400
Net loss for the year	,							,
– as previously stated	_	_	_	_	_	_	(76,197)	(76,197)
Change in accounting policies								` ′ ′
- provision for long service payment								
for the year	_	_	-	_	_	_	(4)	(4)
Net loss for the year (as restated)	-	-	-	-	-	-	(76,201)	(76,201)
At 31 December 2001 (as restated)	260,375	271,195	33,474	_	_	198	(132,797)	432,445
Issue of new shares	25,450	45,810	_	_	_	_	-	71,260
Share issue expenses	_	(1,790)	-	_	_	_	_	(1,790)
Exchange fluctuation								
on translation of								
overseas subsidiaries	_	_	-	-	-	(187)	-	(187)
Net loss for the year	-	-	-	-	-	-	(322,718)	(322,718)
Transfer of reserves	-	-	-	957	478	-	(1,435)	_
At 31 December 2002	285,825	315,215	33,474	957	478	11	(456,950)	179,010

Notes:-

- (i) No goodwill/negative goodwill remains eliminated against reserves at the balance sheet date.
- (ii) The Group's contributed surplus is derived from the difference between the nominal value of the Company's shares issued pursuant to the Group reorganisation in 1991 and the nominal value of the shares acquired.
- (iii) In accordance with the Company Law of the PRC and the Articles of Association of a subsidiary, Huayi Pharmaceutical Company Limited ("Huayi"), Huayi shall appropriate ten percent and five percent of its annual statutory net profit (after offsetting any prior years' losses) to the Statutory Surplus Reserve (儲備基金) and Enterprise Development Fund (企業發展基金) respectively.